Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27.
Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment options. Because these agents were developed concurrently within a short period of time, prospective data on their sequential use efficacy are scarce. The challenge now is to reach a consensus on the best way to sequence effective treatments, ideally by the use of an approach specific to patient subgroups. However, the absence of robust surrogates of survival and the lack of predictive biomarkers makes data for the sequential use of these agents difficult to obtain and interpret.
直到 2010 年，多西他赛是唯一被证实对去势抵抗性前列腺癌有生存获益的药物。卡巴他赛、醋酸阿比特龙、恩扎鲁胺、镭-223 和 sipuleucel-T 的开发增加了治疗选择的数量。由于这些药物是在短时间内同时开发的，因此关于它们序贯使用效果的前瞻性数据很少。现在的挑战是就最佳的治疗方法达成共识，理想情况下是通过针对患者亚组的特定方法。然而，由于缺乏生存的可靠替代指标和预测生物标志物，这些药物序贯使用的数据很难获得和解释。
